Ursula Grohmann
Via Del Liceo N.1
Perugia, 06123, Italy
Perugia, 06123, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls.
Journal: International journal of molecular sciences
Published: March 10, 2022
Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Journal: Inflammatory bowel diseases
Published: February 04, 2022
Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation.
Journal: Current opinion in immunology
Published: August 15, 2021
Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity.
Journal: Frontiers in immunology
Published: May 24, 2021
3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.
Journal: Nature communications
Published: May 11, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme.
Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme.
Journal: The FEBS journal
Published: April 12, 2021
Current Challenges for IDO2 as Target in Cancer Immunotherapy.
Journal: Frontiers in immunology
Published: March 12, 2021
The Landscape of AhR Regulators and Coregulators to Fine-Tune AhR Functions.
Journal: International journal of molecular sciences
Published: December 04, 2020
Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation.
Journal: Human molecular genetics
Published: October 19, 2020
Reply to Han et al.: On track for an IDO1-based personalized therapy in autoimmunity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 30, 2020
Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?
Journal: Biomolecules
Published: July 22, 2020
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: June 25, 2020
Last Updated: 09/26/2026